BRPI0607536A2 - tratamento de dor - Google Patents

tratamento de dor

Info

Publication number
BRPI0607536A2
BRPI0607536A2 BRPI0607536-3A BRPI0607536A BRPI0607536A2 BR PI0607536 A2 BRPI0607536 A2 BR PI0607536A2 BR PI0607536 A BRPI0607536 A BR PI0607536A BR PI0607536 A2 BRPI0607536 A2 BR PI0607536A2
Authority
BR
Brazil
Prior art keywords
pain
treating
treatment
pain treatment
mammal
Prior art date
Application number
BRPI0607536-3A
Other languages
English (en)
Inventor
Sharon Rozenzweig
Michael R Brandt
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0607536A2 publication Critical patent/BRPI0607536A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

TRATAMENTO DE DOR. A presente invenção refere-se a um método de tratar dor em um mamífero, que inclui administrar a um mamífero em necessidade de tal tratamento, uma quantidade eficaz para tratar dor de um composto da fórmula I: ou um sal farmaceuticamente aceitável deste, em que cada de R^ 1^, R^ 2^, R^ 3^, n, y, e Ar é como definido e descrito aqui. A presente invenção também refere-se a composições farmacêuticas para tratar dor contendo uma quantidade eficaz do composto de fórmula I para tratar dor.
BRPI0607536-3A 2005-04-22 2006-04-21 tratamento de dor BRPI0607536A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67408705P 2005-04-22 2005-04-22
PCT/US2006/015217 WO2006116171A1 (en) 2005-04-22 2006-04-21 Treatment of pain

Publications (1)

Publication Number Publication Date
BRPI0607536A2 true BRPI0607536A2 (pt) 2009-09-15

Family

ID=36793862

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607536-3A BRPI0607536A2 (pt) 2005-04-22 2006-04-21 tratamento de dor

Country Status (11)

Country Link
US (1) US20060258713A1 (pt)
EP (1) EP1871354A1 (pt)
JP (1) JP2008538578A (pt)
CN (1) CN101189004A (pt)
AU (1) AU2006239943A1 (pt)
BR (1) BRPI0607536A2 (pt)
CA (1) CA2605117A1 (pt)
GT (1) GT200600160A (pt)
MX (1) MX2007013023A (pt)
TW (1) TW200639159A (pt)
WO (1) WO2006116171A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
MX2007012882A (es) * 2005-04-22 2007-12-10 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento o prevencion de la depresion.
WO2006116170A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
CA2605447A1 (en) * 2005-04-22 2006-11-02 Wyeth Therapeutic combinations for the treatment or prevention of psychotic disorders
CA2605554A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
CA2605435A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
BRPI0610027A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp derivados de cromano e cromeno e usos dos mesmos
PE20061298A1 (es) * 2005-04-22 2006-12-24 Wyeth Corp Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
KR20080009295A (ko) * 2005-04-22 2008-01-28 와이어쓰 벤조디옥산 및 벤조디옥솔란 유도체 및 이의 용도
CA2647048A1 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902267D0 (sv) * 1999-06-16 1999-06-16 Astra Ab New compounds
WO2003037900A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazolopyrimidines
US7728155B2 (en) * 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
PE20061319A1 (es) * 2005-04-22 2006-12-28 Wyeth Corp Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2-3-dihidro-1-benzofurano-2-il]metil}amina
CA2605435A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
WO2006116170A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
US20060258711A1 (en) * 2005-04-22 2006-11-16 Wyeth Treatment of drug abuse
CA2605447A1 (en) * 2005-04-22 2006-11-02 Wyeth Therapeutic combinations for the treatment or prevention of psychotic disorders
CA2605554A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
MX2007012882A (es) * 2005-04-22 2007-12-10 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento o prevencion de la depresion.
BRPI0610027A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp derivados de cromano e cromeno e usos dos mesmos
PE20061298A1 (es) * 2005-04-22 2006-12-24 Wyeth Corp Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
KR20080009295A (ko) * 2005-04-22 2008-01-28 와이어쓰 벤조디옥산 및 벤조디옥솔란 유도체 및 이의 용도
BRPI0609952A2 (pt) * 2005-04-24 2010-05-11 Wyeth Corp métodos para modular a função da bexiga

Also Published As

Publication number Publication date
WO2006116171A1 (en) 2006-11-02
TW200639159A (en) 2006-11-16
GT200600160A (es) 2007-03-14
US20060258713A1 (en) 2006-11-16
JP2008538578A (ja) 2008-10-30
MX2007013023A (es) 2007-12-13
CA2605117A1 (en) 2006-11-02
CN101189004A (zh) 2008-05-28
EP1871354A1 (en) 2008-01-02
AU2006239943A1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
AR060089A1 (es) Tratamiento del dolor
BRPI0607536A2 (pt) tratamento de dor
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
BR112012009215A2 (pt) "terapia combinada contra o cancer com compostos inibidores de hsp90"
BRPI0411241A (pt) agentes terapêuticos úteis para o tratamento de dor
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR0314699A (pt) Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
BRPI0512213A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BR112013029240A2 (pt) derivados deuterados do ivacaftor
BRPI0416656A (pt) compostos de pirrolopirimidina úteis no tratamento do cáncer
BRPI0415167A (pt) composto de amina como ligandos de canal de ìon e usos dos mesmos
BR112014000240A2 (pt) derivados de benzilamina como inibidores de calicreína plasmática
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BRPI0418166A (pt) compostos de bicicloeteroarilamina como ligandos de canal de ìon e usos destes
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
PH12014500239A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112012006010A2 (pt) composto de glicina
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired